Quality over quantity, a more tenured sales force, and yes, even some exciting double-digit growth were bright spots for pharma
in 2008, a year which saw company giants begin to rightsize their sales forces and pull back from the "arms race" mentality.
The number of reps dropped by as much as 8 percent by May, when the Hay Group Annual Sales Force Effectiveness Study was conducted—signaling,
for many companies, a more turbulent year ahead.
With these reports, amid economic uncertainty, one might speculate that those who are employed are staying put. The fact is
that even with fewer sales reps overall, they're still in demand ... and they're still on the move. Certain segments of the
industry are expanding—a fact not lost on sales staff, as voluntary turnover has remained high, or even increased, among some
employee groups. In this environment, companies dare not become complacent in policies to retain top performers. In fact,
applying extra rigor to human capital during an economic downturn can deliver a sustainable advantage.
Interestingly, the sectors that are expanding are doing so very rapidly, at a rate reminiscent of Big Pharma's bygone era.
Just look at biotechs: Despite the much-publicized layoffs, almost every biotech participating in the survey expected to increase
its sales force by 15 percent or more in 2008. About half of all specialty pharmas planned to expand at that rate, as did
just over 40 percent of small and mid-sized companies. Growth of hospital and specialty reps was projected to slow, but still
see double-digit increases—15 percent and 17 percent, respectively. So, the growth is not hard to find, if you know where
to look. (See "Selective Expansion").
Growth is not hard to find, if you know where to look—namely, outside of Big Pharma. Meanwhile, as the economy and healthcare
industry began to show some cracks, fewer reps expect to voluntarily leave their jobs.
As the overall size of the sales force shrinks, several trends are apparent. For instance, sales reps and managers have become
more tenured. During the hiring frenzy a few years ago, 40 percent of district managers had less than 18 months of experience
in their positions. Today, about 80 percent have at least two years of relevant sales experience.
Industry experience is a key attribute for candidates, and 95 percent of surveyed companies say they aren't shy about poaching
reps from other firms. That fact alone suggests pharma is now a harder industry to break into for college graduates—and others.
While 28 percent of respondents use contract sales organizations (an increase from 20 percent in 2007), almost one-third report
that they never (or infrequently) recruit contract reps into full time positions.
Generally speaking, there is an inverse relationship between the strength of the economy and the rate of turnover; the tighter
the job market, the lower the employee attrition. Because data for the survey were collected in May (before the cracks in
the economy really started to appear), and because certain segments of the industry are expanding at a healthy clip, it follows
that the voluntary attrition rate within sales jobs remained high in the 2008 study. At the time of the study, voluntary turnover
was expected to stay at 2007 levels.
Hay Group research has repeatedly demonstrated that pay is the primary reason why high performers leave jobs—which are the
very people companies want to retain. This explains why 81 percent of surveyed companies have implemented new retention initiatives,
and why about half have formal procedures in place to retain high-potential employees, up from 22 percent in 2005.